Price Chart

Profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
URL https://www.karyopharm.com
Investor Relations URL https://investors.karyopharm.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Nov. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
URL https://www.karyopharm.com
Investor Relations URL https://investors.karyopharm.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Nov. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A